PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines

BACKGROUND: The US Food and Drug Administration (FDA) has approved several immunotherapeutic drugs for cancer since 2010, and many more are still being evaluated in other clinical studies. These inhibitors significantly increase response rates and result in the treatment of patients with advanced ca...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Adv Res
Autors principals: Safi, Mohammed, Ahmed, Hyat, Al-Azab, Mahmoud, Xia, Yun-long, Shan, Xiu, Al-radhi, Mohammed, Al-danakh, Abdullah, Shopit, Abdullah, Liu, Jiwei
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020146/
https://ncbi.nlm.nih.gov/pubmed/33842004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jare.2020.09.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars